AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03467685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibratory Anesthetic Device (VAD)
Description: This is a handheld \~10cm long tool, battery operated, which provides vibration at a rate of \~150 Hz
Study NCT02258776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate Extract
Description: Pomegranate extract 1000mg will be taken 1/day for 12 weeks.
Study NCT02258776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate Juice
Description: Pomegranate juice 8oz will be consumed 1/day for 12 weeks.
Study NCT02258776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken 1/day for 12 weeks.
Study NCT00566202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Form= capsule, route= oral use. Administration once daily for 8 weeks.
Study NCT00566202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form= capsule, route= oral use. Administration once daily for 8 weeks.
Study NCT00566202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 20 mg daily for 6 weeks, and 10 mg daily for 1 week.
Study NCT00566202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-18038683
Description: Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week.
Study NCT00754156 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: V.A.C. Therapy
Description: V.A.C. Therapy Alone
Study NCT00553228 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap
Description: 0.5 mL IM once at visit #2
Study NCT00553228 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Td
Description: 0.5 mL IM once at visit #2
Study NCT03088670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gosogliptin
Description: 20 mg per day, dose titration to 30 mg per day at Week 4 as required Administration: orally
Study NCT03088670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Description: 50 mg per day, dose titration to 100 mg per day at Week 4 as required (50 mg twice a day) Administration: orally
Study NCT03088670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1000 mg per day starting Week 12 (500 mg twice a day), dose titration to 2000 mg per day at Week 16 as required (1000 mg twice a day).~Administration: orally
Study NCT03088670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000 mg per day starting Week 12 (500 mg twice a day), dose titration to 2000 mg per day at Week 16 as required (1000 mg twice a day).~Administration: orally
Study NCT02697331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: women will receive progesterone vaginal pesarries containing 200mg of progesterone twice daily . it will be used by the patient as one vaginal pessary per vagina twice per day .~women will be showed how to use tablets . medication will be started at 20 -24 weeks and stopped at 36+6 weeks
Study NCT02697331 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: women will receive placebo pessary twice a day. women will be showed how to use tablets . medication will be started at 20-24 weeks and stopped at 36+6 weeks
Study NCT00003674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalteparin
Study NCT00003674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy
Study NCT00003674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy
Study NCT02222805 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Early (≤30 seconds) cord clamping
Description: Early (≤30 seconds) cord clamping of the umbilical cord after delivery.
Study NCT02222805 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Delayed (≤180 seconds) cord clamping
Description: Delayed (≤180 seconds) cord clamping of the umbilical cord after delivery.
Study NCT00846495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topiramate
Description: topiramate 25mg 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 2 tabs in PM x 1 week topiramate 25mg 2 tabs in AM / 2 tabs in PM x 5 weeks
Study NCT00846495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: frovatriptan
Description: frovatriptan 5mg tab during premonitory phase of migraine
Study NCT02107092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate
Description: Oral 10g once daily with breakfast for 11 months.
Study NCT02597101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: background drug
Study NCT02597101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: background drug
Study NCT00566202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-18038683
Description: Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week.
Study NCT01431638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab 150mg in prefilled syringe
Description: Canakinumab 150mg in prefilled syringe will be given in a single dose subcutaneously upon demand for gouty arthritis flares
Study NCT02597101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: background drug
Study NCT02597101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saxagliptin
Description: background drug
Study NCT02597101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: study drug
Study NCT00754156 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KCI ABThera
Description: KCI ABThera
Study NCT02684305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Propess
Description: 1. History taking and physical examination including cervical length~2. Eligibility assessment~3. Explanation regarding the study protocol~4. Signed informed consent (at VAS\<3)~5. Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum.
Study NCT02597101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for AZD9668 to be added to background drugs
Study NCT04561622 — intervention group
Intervention type: BEHAVIORAL
Intervention: Emotional Stroop Task
Description: Classic Stroop task The subject names one of the 3 colors of the crosses on a sheet.Then, the subject must read the words written on the sheet for 45 seconds.These are the words: RED, BLUE and GREEN, written in black color. The subject must name the color of the word.~Emotional Stroop task This is a computed task in which the patient is asked to answer both as accurately and as quickly as possible.~The target stimulus is an emotional face of joy or anger, surmounted by the word joy or anger.The subject must respond using the arrow corresponding to the face he sees.~A training phase is offered to the subject.~3 / Categorization task For each trial the participant will visualize a short emotional film or not. Then, the participant will have to choose, the emotion corresponding to what he just saw. A training period is offered too.
Study NCT00563264 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: KAN-DO
Description: The 10 month KAN-DO intervention includes eight mailed interactive activity modules involving both the preschooler and mother that include relevant printed materials emphasizing parenting skills, healthy eating habits and increased physical activity. Mailed kits will each be followed by a supportive telephone counseling session based on motivational interviewing techniques. Mailed modules and telephone calls will be supplemented with two in-person motivational and informational sessions (at the beginning and in the middle of the intervention period).~The Active Comparator group will receive monthly newsletters over the 10 month period related to boosting reading skills in their preschool children.
Study NCT00563264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KAN-DO
Description: The 10 month KAN-DO intervention includes eight mailed interactive activity modules involving both the preschooler and mother that include relevant printed materials emphasizing parenting skills, healthy eating habits and increased physical activity. Mailed kits will each be followed by a supportive telephone counseling session based on motivational interviewing techniques. Mailed modules and telephone calls will be supplemented with two in-person motivational and informational sessions (at the beginning and in the middle of the intervention period).~The Active Comparator group will receive monthly newsletters over the 10 month period related to boosting reading skills in their preschool children.
Study NCT01414972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: 1 cap vitamin A 25000 IU/day for 3 month
Study NCT01414972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 cap placebo/day for 3 month
Study NCT02684305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon
Description: 1. History taking and physical examination including cervical length~2. Eligibility assessment~3. Explanation regarding the study protocol~4. Signed informed consent (at VAS\<3)~5. Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum.
Study NCT00911898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-111
Description: For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV
Study NCT02187562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Study NCT02187562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT02187562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study NCT02146261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: Subcutaneous administration of E6011 (at doses of 50, 100, 200 and 400 mg)
Study NCT02146261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous administration of placebo
Study NCT03608722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SLUMS
Description: A pen and paper screening tool of cognitive impairment
Study NCT03608722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MMSE
Description: A pen and paper screening tool of cognitive impairment
Study NCT03608722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MoCA
Description: A pen and paper screening tool for cognitive impairment
Study NCT02684305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin infusion
Description: 1. History taking and physical examination including cervical length~2. Eligibility assessment~3. Explanation regarding the study protocol~4. Signed informed consent (at VAS\<3)~5. Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum.
Study NCT03957967 — intervention group
Intervention type: OTHER
Intervention: video taken
Description: Patients enrolled will be operated in our institution. Facial expression will be collected before and after surgery, and pain intensity will be collected at the same time. Facial expression will be analyzed using Facial Action Coding System (FACS) .This step will seek to confirm that the subset of Action Units (AUs) defined in previous studies is correlated with the presence and intensity of an acute pain or to identify a different original subset of facial AUs better correlated to pain intensity. . The developed algorithm (or model) here should be able to correlate facial AUs to pain intensity reported by the patients on the numerical rating scale. The developed model at this stage will be then validated on an additional sample of patients.
Study NCT03608722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainCheck
Description: A computerized neurocognitive test administered via an electronic device, such as a phone, tablet or computer, that contains several assessments that will aid in establishing an individuals cognitive performance
Study NCT04132908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: nutraceutical
Description: Subjects will consume two capsules at breakfast and dinner for ten weeks.
Study NCT04132908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will consume two capsules at breakfast and dinner for ten weeks.
Study NCT00585689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: ABI-007 will be administered at a dose of 260 mg/m2 over a 30 min IV infusion on day 1 of each 21 day cycle.
Study NCT00585689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered at a dose of TARGET AUC=5 over a 15 min IV infusion of day 1 of each 21 day cycle.
Study NCT00585689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered at a dose of 800 mg/m2 over a 30 min IV infusion on days 1 and 8 of each 21 day cycle.
Study NCT00585689 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Study NCT04606420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle medicine
Description: Diet: A low fat (10-15%) whole foods vegan diet, high in complex carbs and low in refined carbs (fruits, vegetables, whole grains, legumes, soy, seeds \& nuts). Calories unrestricted. Multivitamin, fish oil, curcumin, vitamin C, B12, CoQ10, lion's mane, probiotic, and magnesium. 21 meals/week and supplements provided to participants and caregivers at no cost to them.~Exercise: Aerobic (e.g., walking) and strength training 30 minutes/day based on a personalized prescription from an exercise physiologist or certified personal trainer and registered nurse.~Stress Management: Meditation, gentle yoga-based poses, progressive relaxation, breathing exercises, and meditation (with optional glasses) 1 hour per day, supervised by a certified stress management specialist.~Group Support: Participants and their spouses/caregivers participate in a support group one hour/session, 3 days/week, supervised by a licensed mental health professional in a supportive, safe environment.
Study NCT00984126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
Study NCT00984126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
Study NCT00507663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: Patients with a standing prescription for β-blockers will be continued on that medication. Pts not currently receiving a beta blocker will be given 50mg of atenolol on the morning of surgery, 50-100mg, twice per day, on the first postoperative day until postoperative day 7.
Study NCT03099174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xentuzumab
Description: Once weekly administrated through one hour intravenous infusion
Study NCT03099174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort A) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours
Study NCT03099174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Once a day
Study NCT03099174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Once a day
Study NCT03099174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Once a month, with an additional dose given two weeks after the first dose. Each dose is given as two slow injections lasting one to two minutes, with one injection being given into the muscle of each buttock
Study NCT03099174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort D) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours
Study NCT04110652 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pulmonary rehabilitation program
Description: The pulmonary rehabilitation program consisting of inspiratory muscle training, manual hyperinflation. chest wall mobilization, rib-cage compression, cough function training, postural drainage and secretion removal will be applied to patient group.~The program will be conducted by physical therapists for 30-45 minutes daily during ICU stay.~The exercise intensity will be increased gradually over the course. Each patient's performance during the exercise sessions will be recorded and reported regularly.
Study NCT03921996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy (RP) followed by ePLND
Description: ePLND is performed either before or after radical prostatectomy and includes the removal of all nodal and fibro-fatty tissue
Study NCT03921996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical prostatectomy (RP) only
Description: Radical prostatectomy
Study NCT04297358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: 40 consecutive (5/7) sessions of hyperbaric oxygen
Study NCT03482869 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: walking ability
Description: Included patients will perform a 6 min walk test
Study NCT03499509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glycemic Diet
Description: Low Glycemic (LG) diet: The LG diet will be made up of foods that do not stimulate insulin secretion. The foods that make up the diet will differ depending on the phase of the study. During the weight loss phase, breakfast and lunch will each consist of one or two meal-replacement shakes (e.g., High-Protein SlimFast). Dinner will be a frozen entrée (e.g., Atkins, Lean Cuisine, Healthy Choice) supplemented with a side of vegetables. Snacks will be nuts, berries, and full-fat dairy products (one serving per day), and will be used to adjust the calorie level of each day's meals to individual calorie needs.
Study NCT03499509 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High Glycemic Diet
Description: High Glycemic (HG) diet: The HG diet will conform to United States Department of Agriculture (USDA) guidelines (http://health.gov/dietaryguidelines/2015/guidelines/). The foods that make up the diet will differ depending on the phase of the study. During the weight loss phase, breakfast and lunch will each consist of one or two meal-replacement shakes (e.g., SlimFast). Dinner will be a frozen entrée (e.g., Lean Cuisine, Healthy Choice) supplemented with a side of vegetables. Snacks will be fruit, fat-free dairy products, and low-fat bars (e.g., Optifast), and will be used to adjust the calorie level of each day's meals to individual calorie needs.
Study NCT02666326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accelerated, combined biomarker rule-out strategy for MI
Description: Blood sample is acquired while the patient is in the ambulance. This is brought to hospital and handed over to the laboratory personnel for acute analysis for copeptin level. At arrival to hospital, a second blood sample is acquired and analyzed for high-sensitive cardiac troponin-T(hs-cTnT). Answers of these analyzes are in-hand with-in 60 minutes. If copeptin in the pre-hospital blood sample is \<9,8 pmol/L (95% percentile) AND hs-cTnT in the in-hospital blood sample is \<14ng/L (99% percentile), then myocardial infarction can be ruled out, and depending of clinical presentation, the patient can be discharged.